Research programme: hepatitis C therapy - Crucell

Drug Profile

Research programme: hepatitis C therapy - Crucell

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer Crucell
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in Netherlands (Parenteral)
  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
  • 06 May 2009 Preclinical trials in Hepatitis C in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top